This brand name is authorized in Brazil, Hong Kong, Japan, Turkey
The drug BERIPLAST-P contains a combination of these active pharmaceutical ingredients (APIs):
1
Human plasma protein fraction (Fibrinogen)
UNII N94833051K - FIBRINOGEN HUMAN
|
Human fibrinogen (coagulation factor I), in the presence of thrombin, activated coagulation factor XIII (F XIIIa) and calcium ions is converted into a stable and elastic three-dimensional fibrin haemostatic clot. The administration of human fibrinogen concentrate provides an increase in plasma fibrinogen level and can temporarily correct the coagulation defect of patients with fibrinogen deficiency. |
2
Clotting human protein plasma fraction (Factor XIII)
UNII F7R0FBC1XD - FACTOR XIII CONCENTRATE (HUMAN)
|
Factor XIII connects the amino group of lysine with glutamine via its enzymatic function (transamidase activity), thereby leading to the cross-linking of fibrin molecules. This is the final stage of blood coagulation. Fibrin cross-linking and stabilisation promote the penetration of fibroblasts and support wound healing. |
3
Aprotinin from bovine lung
UNII 04XPW8C0FL - APROTININ
|
Aprotinin is a broad spectrum protease inhibitor which has antifibrinolytic properties. By forming reversible stoichiometric enzyme-inhibitor complexes, aprotinin acts as an inhibitor of human trypsin, plasmin, plasma kallikrein and tissue kallikrein, thus inhibiting fibrinolysis. |
4
Human plasma protein fraction (Thrombin)
UNII 25ADE2236L - THROMBIN
|
|
5
Calcium chloride dihydrate
UNII M4I0D6VV5M - CALCIUM CHLORIDE
|
Calcium is the most abundant mineral in the body, and is an essential body electrolyte. Homeostasis is mainly regulated by the parathyroid hormone, by calcitonin, and by the activated form of vitamin D. Calcium is a structural component of bones and teeth. It is also required for blood clotting, neurotransmitter release, muscle contraction and normal heartbeat. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
B02BC | Local hemostatics | B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics |
B02BC30 | Combinations | B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BC Local hemostatics |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: BR | Câmara de Regulação do Mercado de Medicamentos | Identifier(s): 502600602158416, 502600603154414 |
Country: HK | Department of Health Drug Office | Identifier(s): 48635, 48636 |
Country: JP | 医薬品医療機器総合機構 | Identifier(s): 6349800X1021, 6349800X2028, 6349800X3024, 6349800X4020 |
Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8681624980057 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.